Mild Cognitive Impairment - Pipeline Review, H2 2016

Date: September 30, 2016
Pages: 111
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M9BE88F6C25EN
Leaflet:

Download PDF Leaflet

Mild Cognitive Impairment - Pipeline Review, H2 2016
Mild Cognitive Impairment - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2016, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 8, 1, 11 and 1 respectively for Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively for Mild Cognitive Impairment.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Mild Cognitive Impairment Overview
Therapeutics Development
Pipeline Products for Mild Cognitive Impairment - Overview
Pipeline Products for Mild Cognitive Impairment - Comparative Analysis
Mild Cognitive Impairment - Therapeutics under Development by Companies
Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
Mild Cognitive Impairment - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Mild Cognitive Impairment - Products under Development by Companies
Mild Cognitive Impairment - Products under Investigation by Universities/Institutes
Mild Cognitive Impairment - Companies Involved in Therapeutics Development
AbbVie Inc
AgeneBio Inc.
Avraham Pharmaceuticals Ltd.
CereSpir Incorporated
Eisai Co., Ltd.
Eli Lilly and Company
Ensol Biosciences Inc.
Genzyme Corporation
IntelGenx Corp.
Krenitsky Pharmaceuticals Inc.
Nanotherapeutics, Inc.
Neuron Biopharma SA
Octapharma AG
Sage Therapeutics, Inc.
Suven Life Sciences Ltd.
Takeda Pharmaceutical Company Limited
Therapix Biosciences Ltd.
Mild Cognitive Impairment - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABT-957 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAN-2401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSP-1103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSTI-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAOI-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-544 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladostigil tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levetiracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-2599666 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3002813 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3303560 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
montelukast sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Moriah-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-0158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-0163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0037 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTC-942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pioglitazone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-507 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVN-512 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropisetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mild Cognitive Impairment - Dormant Projects
Mild Cognitive Impairment - Discontinued Products
Mild Cognitive Impairment - Product Development Milestones
Featured News & Press Releases
Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast
Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment
Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment
Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m
Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer’s Disease At ICAD 2009, Vienna, Austria.
Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland
Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London
Sep 29, 2008: Suven Completes Phase-I Clinical Trials Single Ascending Dose Of Suvn-502 In Switzerland
Sep 25, 2008: Suven Life Sciences Ltd. Announces DCGI Nod To Conduct Phase-I Clinical Trials Of Suvn-502 For Alzheimer’S Disease
Aug 04, 2008: Suven Life Sciences Presents Positive Preclinical Data for Suvn-502 at Alzheimer’S Conference, Chicago and Drug Discovery Conference, Boston
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 111

LIST OF TABLES

Number of Products under Development for Mild Cognitive Impairment, H2 2016
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Mild Cognitive Impairment - Pipeline by AbbVie Inc, H2 2016
Mild Cognitive Impairment - Pipeline by AgeneBio Inc., H2 2016
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2016
Mild Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2016
Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2016
Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2016
Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H2 2016
Mild Cognitive Impairment - Pipeline by Genzyme Corporation, H2 2016
Mild Cognitive Impairment - Pipeline by IntelGenx Corp., H2 2016
Mild Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
Mild Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H2 2016
Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2016
Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2016
Mild Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H2 2016
Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2016
Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Mild Cognitive Impairment - Dormant Projects, H2 2016
Mild Cognitive Impairment - Dormant Projects (Contd..1), H2 2016
Mild Cognitive Impairment - Discontinued Products, H2 2016 99

LIST OF FIGURES

Number of Products under Development for Mild Cognitive Impairment, H2 2016
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Mild Cognitive Impairment - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 109 pages
Mild Cognitive Impairment - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Memory Impairment - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 64 pages
Memory Impairment - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 70 pages

Ask Your Question

Mild Cognitive Impairment - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: